JP2016520077A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520077A5
JP2016520077A5 JP2016513459A JP2016513459A JP2016520077A5 JP 2016520077 A5 JP2016520077 A5 JP 2016520077A5 JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016520077 A5 JP2016520077 A5 JP 2016520077A5
Authority
JP
Japan
Prior art keywords
polypeptide
hcv
hcv genotype
genotype
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016513459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/001972 external-priority patent/WO2015132619A1/en
Publication of JP2016520077A publication Critical patent/JP2016520077A/ja
Publication of JP2016520077A5 publication Critical patent/JP2016520077A5/ja
Withdrawn legal-status Critical Current

Links

JP2016513459A 2013-05-15 2014-05-15 E1e2hcvワクチン及び使用方法 Withdrawn JP2016520077A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US61/823,712 2013-05-15
US201361887229P 2013-10-04 2013-10-04
US61/887,229 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087976A Division JP2019142962A (ja) 2013-05-15 2019-05-08 E1e2 hcvワクチン及び使用方法

Publications (2)

Publication Number Publication Date
JP2016520077A JP2016520077A (ja) 2016-07-11
JP2016520077A5 true JP2016520077A5 (https=) 2017-06-22

Family

ID=54054625

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016513459A Withdrawn JP2016520077A (ja) 2013-05-15 2014-05-15 E1e2hcvワクチン及び使用方法
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 E1e2 hcvワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 E1e2 hcvワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 E1e2 hcvワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 E1e2 hcvワクチン及び使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 E1e2 hcvワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 E1e2 hcvワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 E1e2 hcvワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 E1e2 hcvワクチン及び使用方法

Country Status (8)

Country Link
US (3) US20210145963A9 (https=)
EP (2) EP3689375A1 (https=)
JP (5) JP2016520077A (https=)
CN (2) CN105263517B (https=)
AU (3) AU2014385320B2 (https=)
CA (1) CA2909586C (https=)
CL (1) CL2015003333A1 (https=)
WO (1) WO2015132619A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3000313A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
EP3515483A4 (en) * 2016-09-21 2020-12-16 The Governors of the University of Alberta HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES
AU2017341735B2 (en) * 2016-10-11 2022-01-13 Helmholtz Center for Infection Research Hepatitis C virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof
CN112601548A (zh) * 2018-03-16 2021-04-02 艾伯塔大学理事会 丙型肝炎病毒肽组合物及其使用方法
WO2025222304A1 (en) * 2024-04-26 2025-10-30 The Governors Of The University Of Alberta Hcv genotype3 e2 envelope protein for neutralizing infectivity of hcv strains

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2288374A1 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
CZ20021043A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
CZ20033515A3 (cs) * 2001-06-29 2005-01-12 Chiron Corporation Kompozice vakcíny HCV E1E2
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
US8603468B2 (en) * 2007-11-06 2013-12-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Neutralization of HCV
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
Filippelli et al. Hepatitis B vaccine by intradermal route in non responder patients: an update
van Riet et al. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
Nichol et al. Vaccines for seasonal and pandemic influenza
JP2017524682A5 (https=)
JP2019151636A5 (https=)
JP2016520077A5 (https=)
Ross et al. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice
HRP20201953T1 (hr) Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b
JP2016531144A5 (https=)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2018523668A5 (https=)
RU2017137357A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
RU2020117033A (ru) Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение
Romeli et al. Multi-epitope peptide-based and vaccinia-based universal influenza vaccine candidates subjected to clinical trials
JP2012526839A5 (https=)
JP2018505882A5 (https=)
JP2016508999A5 (https=)
JP2019531293A5 (https=)
FI3166615T3 (fi) Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
JP2017512194A5 (https=)
JP2014058541A5 (https=)
Bhandari et al. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
JP2019510064A5 (https=)